Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ExtendicareEXETF -1.79%76 EV-to-EBITDA is 15.24 as of Jul. 16, 2026, which is 24% above its 10-year median of 12.33. GuruFocus rates EXETF with a GF Score™ of 76/100 and a GF Value™ of $10.18 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 507 Healthcare Providers & Services companies, Extendicare ranks worse than 66.47% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Extendicare's enterprise value is $2,429 Mil.
Extendicare's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $159 Mil. Therefore, Extendicare's EV-to-EBITDA for today is 15.24.
The historical rank and industry rank for Extendicare's EV-to-EBITDA or its related term are showing as below:
EXETF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.35 Med: 12.33 Max: 20.03
Current: 15.24
During the past 13 years, the highest EV-to-EBITDA of Extendicare was 20.03. The lowest was 6.35. And the median was 12.33.
EXETF's EV-to-EBITDA is ranked worse than 66.47% of 507
companies
in the Healthcare Providers & Services industry
Industry Median: 11.03
vs EXETF: 15.24
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Extendicare's PE Ratio (TTM) for today is calculated as:
Extendicare's share price for today is $26.164.
Extendicare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.990.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Extendicare's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Extendicare's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Extendicare EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Extendicare's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Extendicare's EV-to-EBITDA falls into.
Extendicare's current Enterprise Value is $2,429 Mil.
Extendicare's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $159 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Extendicare (EXETF) has a EV-to-EBITDA of 15.24 as of Jul. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Extendicare. This is 24% above median its historical median of 12.33. Over the past decade, Extendicare's EV-to-EBITDA has ranged from 6.35 to 20.03. According to the industry distribution chart, Extendicare ranks #337 out of 507 companies in the Healthcare Providers & Services industry, placing it in the top 66.5%.
Is Extendicare's EV-to-EBITDA too high?
Extendicare's current EV-to-EBITDA of 15.24 is 24% above median its 10-year median of 12.33. Over the past 10 years, this metric has ranged from a low of 6.35 to a high of 20.03. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.03. Extendicare's value of 15.24 is 38.2% above this industry median. Based on the distribution chart, Extendicare ranks #337 out of 507 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Extendicare has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Extendicare's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Extendicare ranks #337 out of 507 companies for EV-to-EBITDA. This places Extendicare in the lower half of its industry. The industry median EV-to-EBITDA is 11.03. Extendicare's value of 15.24 is 38.2% above this benchmark. Historically, Extendicare's own EV-to-EBITDA has ranged from 6.35 to 20.03 over the past decade. While the company's 10-year median is 12.33 vs. the industry median of 11.03, Extendicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.03, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Extendicare's current EV-to-EBITDA of 15.24 is 38.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Extendicare. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Extendicare's current EV-to-EBITDA is 15.24, which is 24% above median its own 10-year median of 12.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extendicare stock overvalued right now?
Based on GuruFocus' analysis, Extendicare (EXETF) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.18, compared to a current price of $26.16 — trading 157% above its estimated fair value. The current EV-to-EBITDA is 15.24, which is 24% above median its 10-year median of 12.33 and 38.2% above the Healthcare Providers & Services industry median of 11.03. Extendicare's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Extendicare (EXETF), the current EV-to-EBITDA is 15.24 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Extendicare (EXETF) Overvalued in 2026?
Based on GuruFocus' analysis, Extendicare stock appears to be overvalued.
The current stock price of $26.16 is trading 157% above its estimated GF Value™ of $10.18.
GuruFocus considers Extendicare to be Significantly Overvalued.
Key valuation signals for EXETF:
EV-to-EBITDA: 15.24 (24% above median its 10-year median of 12.33)
GF Value™: $10.18 vs. price of $26.16 (157% above fair value)
Industry Position: 38.2% above the Healthcare Providers & Services median (#337 of 507)
No single metric tells the full story. See the EXETF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Extendicare Inc is a senior care provider in Canada, focused on long-term care and home health care. The has three main business segments: Long-term Care (LTC), Home Health Care, and Managed Services. The Long-term Care segment, operating under the Extendicare brand, represents 53 owned homes in Ontario, Alberta and Manitoba. The Home Health Care segment, operating under the ParaMed brand, provides home health care services annually in Ontario, Alberta, Manitoba and Nova Scotia. The Managed Services segment, operating under the Extendicare Assist and SGP Purchasing Partner Network brands, provides management, consulting and group purchasing services to other care providers across Canada. The majority of the company's revenue is derived from the Long-term Care segment.
76GF Score
Get the complete analysis for EXETF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EXETF has been successfully added to your 
